Quantcast
Home > Quotes > LJPC
LJPC

La Jolla Pharmaceutical Company Common Stock (LJPC) Quote & Summary Data

$31.78
*  
0.85
2.6%
Get LJPC Alerts
*Delayed - data as of May 22, 2018  -  Find a broker to begin trading LJPC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
56
Today's High / Low
$ 33.09 / $ 31.73
Share Volume
345,251
50 Day Avg. Daily Volume
511,846
Previous Close
$ 32.63
52 Week High / Low
$ 41.359 / $ 22.68
Market Cap
831,188,071
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.86

Intraday Chart

Shares Traded

Share Volume:
345,251
50 Day Avg. Daily Volume:
511,846

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -6.36

Trading Range

The current last sale of $31.78 is 40.12% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 33.09 $ 41.359
 Low: $ 31.73 $ 22.68

Company Description (as filed with the SEC)

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II), formerly known as LJPC-501, was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is our first commercial product. LJPC-401, a clinical-stage investigational product, is our proprietary formulation of synthetic human hepcidin. LJPC-401 is being developed for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome.  ... More ...  

Risk Grade

Where does LJPC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 32.62
Open Date:
May 22, 2018
Close Price:
$ 31.78
Close Date:
May 22, 2018

Consensus Recommendation

Analyst Info